116 related articles for article (PubMed ID: 25482338)
1. Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases.
Jin L; Boyd BJ; White PJ; Pennington MW; Norton RS; Nicolazzo JA
J Control Release; 2015 Feb; 199():37-44. PubMed ID: 25482338
[TBL] [Abstract][Full Text] [Related]
2. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa.
Jin L; Boyd BJ; Larson IC; Pennington MW; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Jul; 105(7):2173-9. PubMed ID: 27312508
[TBL] [Abstract][Full Text] [Related]
3. The buccal mucosa as an alternative route for the systemic delivery of risperidone.
Heemstra LB; Finnin BC; Nicolazzo JA
J Pharm Sci; 2010 Nov; 99(11):4584-92. PubMed ID: 20845457
[TBL] [Abstract][Full Text] [Related]
4. Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system.
Langoth N; Kahlbacher H; Schöffmann G; Schmerold I; Schuh M; Franz S; Kurka P; Bernkop-Schnürch A
Pharm Res; 2006 Mar; 23(3):573-9. PubMed ID: 16411147
[TBL] [Abstract][Full Text] [Related]
5. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of various buccal permeation enhancing systems for PACAP (pituitary adenylate cyclase-activating polypeptide).
Langoth N; Bernkop-Schnürch A; Kurka P
Pharm Res; 2005 Dec; 22(12):2045-50. PubMed ID: 16132338
[TBL] [Abstract][Full Text] [Related]
7. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.
Chi V; Pennington MW; Norton RS; Tarcha EJ; Londono LM; Sims-Fahey B; Upadhyay SK; Lakey JT; Iadonato S; Wulff H; Beeton C; Chandy KG
Toxicon; 2012 Mar; 59(4):529-46. PubMed ID: 21867724
[TBL] [Abstract][Full Text] [Related]
8. An integrated buccal delivery system combining chitosan films impregnated with peptide loaded PEG-b-PLA nanoparticles.
Giovino C; Ayensu I; Tetteh J; Boateng JS
Colloids Surf B Biointerfaces; 2013 Dec; 112():9-15. PubMed ID: 23928054
[TBL] [Abstract][Full Text] [Related]
9. Buccal delivery of thiocolchicoside: in vitro and in vivo permeation studies.
Artusi M; Santi P; Colombo P; Junginger HE
Int J Pharm; 2003 Jan; 250(1):203-13. PubMed ID: 12480286
[TBL] [Abstract][Full Text] [Related]
10. Sea Anemones: Quiet Achievers in the Field of Peptide Toxins.
Prentis PJ; Pavasovic A; Norton RS
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316700
[TBL] [Abstract][Full Text] [Related]
11. Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide).
Langoth N; Kalbe J; Bernkop-Schnürch A
Int J Pharm; 2005 May; 296(1-2):103-11. PubMed ID: 15885461
[TBL] [Abstract][Full Text] [Related]
12. A novel tri-layered buccal mucoadhesive patch for drug delivery: assessment of nicotine delivery.
Rao S; Song Y; Peddie F; Evans AM
J Pharm Pharmacol; 2011 Jun; 63(6):794-9. PubMed ID: 21585377
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the buccal mucosa as an alternative route for the delivery of donepezil hydrochloride.
Caon T; Pan Y; Simões CM; Nicolazzo JA
J Pharm Sci; 2014 Jun; 103(6):1643-51. PubMed ID: 24687969
[TBL] [Abstract][Full Text] [Related]
14. Azone® decreases the buccal mucosal permeation of diazepam in a concentration-dependent manner via a reservoir effect.
Meng-Lund E; Jacobsen J; Jin L; Janfelt C; Holm R; Müllertz A; Nicolazzo JA
J Pharm Sci; 2014 Apr; 103(4):1133-41. PubMed ID: 24532052
[TBL] [Abstract][Full Text] [Related]
15. Novel strategies for the buccal delivery of macromolecules.
Morales JO; McConville JT
Drug Dev Ind Pharm; 2014 May; 40(5):579-90. PubMed ID: 24611816
[TBL] [Abstract][Full Text] [Related]
16. Transbuccal delivery of doxepin: studies on permeation and histological investigation.
Gimeno A; Calpena AC; Sanz R; Mallandrich M; Peraire C; Clares B
Int J Pharm; 2014 Dec; 477(1-2):650-4. PubMed ID: 25445535
[TBL] [Abstract][Full Text] [Related]
17. Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile.
Middleton RE; Sanchez M; Linde AR; Bugianesi RM; Dai G; Felix JP; Koprak SL; Staruch MJ; Bruguera M; Cox R; Ghosh A; Hwang J; Jones S; Kohler M; Slaughter RS; McManus OB; Kaczorowski GJ; Garcia ML
Biochemistry; 2003 Nov; 42(46):13698-707. PubMed ID: 14622016
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the buccal mucosal delivery of peptide and protein therapeutics.
Caon T; Jin L; Simões CM; Norton RS; Nicolazzo JA
Pharm Res; 2015 Jan; 32(1):1-21. PubMed ID: 25168518
[TBL] [Abstract][Full Text] [Related]
19. A novel approach to enhance the mucoadhesion of lipid drug nanocarriers for improved drug delivery to the buccal mucosa.
Du JD; Liu Q; Salentinig S; Nguyen TH; Boyd BJ
Int J Pharm; 2014 Aug; 471(1-2):358-65. PubMed ID: 24879939
[TBL] [Abstract][Full Text] [Related]
20. Polyethyleneimine and Chitosan Polymer-Based Mucoadhesive Liquid Crystalline Systems Intended for Buccal Drug Delivery.
Calixto GMF; Victorelli FD; Dovigo LN; Chorilli M
AAPS PharmSciTech; 2018 Feb; 19(2):820-836. PubMed ID: 29019033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
